KDM6B and cancer: GSK‐J4 is an effective dual inhibitor of H3K27me3/me2 demethylases KDM6B and KDM6A, known to promote gene silencing and cell apoptosis by inhibiting KDM6A to regulate histone methylation levels, with applications in cancer treatment.